Avelumab


Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Listed in Dosage.
Liều dùng/Hướng dẫn sử dụng
Adult : IV Metastatic Merkel cell carcinoma 10 mg/kg, or 800 mg once every 2 weeks. Locally advanced or metastatic urothelial carcinoma In patients who have disease progression during or after platinum-based chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy: 800 mg once every 2 weeks. Advanced renal cell carcinoma In combination with axitinib: 800 mg once every 2 weeks. Continue treatment until disease progression or unacceptable toxicity occurs. All doses are given via infusion over 60 minutes. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Dosage Details
Intravenous
Metastatic Merkel cell carcinoma
Adult: 10 mg/kg, or 800 mg via infusion over 60 minutes once every 2 weeks. Continue treatment until disease progression or unacceptable toxicity occurs. Premedicate with antihistamine and paracetamol prior to the 1st 4 infusions. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).

Intravenous
Advanced renal cell carcinoma
Adult: In combination with axitinib: 800 mg via infusion over 60 minutes once every 2 weeks. Continue treatment until disease progression or unacceptable toxicity occurs. Premedicate with antihistamine and paracetamol prior to the 1st 4 infusions. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).

Intravenous
Locally advanced urothelial carcinoma, Metastatic urothelial carcinoma
Adult: In patients who have disease progression during or after platinum-based chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy: 800 mg via infusion over 60 minutes once every 2 weeks. Continue treatment until disease progression or unacceptable toxicity occurs. Premedicate with antihistamine and paracetamol prior to the 1st 4 infusions. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).
Hướng dẫn pha thuốc
Withdraw appropriate volume from the vial then transfer to an IV infusion bag containing 250 mL 0.9% NaCl or 0.45% NaCl solution for inj. Mix the bag by gentle inversion. Do not shake.
Chống chỉ định
Pregnancy and lactation.
Thận trọng
Patient with CV risk factors (e.g. hypertension, diabetes mellitus, dyslipidaemia).
Phản ứng phụ
Significant: Immune-mediated reactions such as colitis, thyroid disorders (e.g. hypo- or hyperthyroidism, thyroiditis), adrenal insufficiency, type 1 diabetes mellitus (including diabetic ketoacidosis), nephritis. Rarely, immune-mediated reactions like myositis, hypopituitarism, uveitis, Guillain-Barré syndrome, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, systemic inflammatory response.
Blood and lymphatic system disorders: Anaemia, lymphopenia, thrombocytopenia.
Gastrointestinal disorders: Nausea, diarrhoea, constipation, vomiting, dry mouth.
General disorders and administration site conditions: Fatigue, asthenia, influenza-like illness.
Immune system disorders: Hypersensitivity.
Investigations: Decreased weight; increased ALT/AST, amylase, lipase, serum creatinine.
Metabolism and nutrition disorders: Decreased appetite, peripheral oedema, hyponatraemia.
Musculoskeletal and connective tissue disorders: Back pain, arthralgia, myalgia.
Nervous system disorders: Headache, dizziness, peripheral neuropathy.
Renal and urinary disorders: Acute renal injury, UTI.
Respiratory, thoracic and mediastinal disorders: Cough, dysphonia.
Skin and subcutaneous tissue disorders: Rash, pruritus, maculo-papular rash, dry skin, cellulitis.
Vascular disorders: Hypertension.
Potentially Fatal: Immune-mediated reactions including pneumonitis, hepatitis; severe infusion-related reactions (e.g. pyrexia, chills, flushing, hypotension, dyspnoea, wheezing, abdominal pain, urticaria). Rarely, immune-mediated myocarditis, pancreatitis; severe CV events (e.g. MI, CHF) when used in combination with axitinib.
Thông tin tư vấn bệnh nhân
This drug may cause fatigue, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor LFTs, serum creatinine, thyroid function tests, blood glucose, and LVEF (in combination with axitinib) at baseline, periodically during therapy, and as clinically indicated. Assess for signs and symptoms of infusion-related reactions, immune-related reactions including pneumonitis, hepatitis, colitis, endocrinopathies (e.g. adrenal insufficiency, hyperglycaemia, thyroid disorders), and CV events (in combination with axitinib).
Tương tác
Potentially Fatal: May cause severe CV events and hepatotoxicity in combination therapy with axitinib.
Tác dụng
Description: Avelumab is a human immunoglobulin G1 monoclonal antibody that selectively binds to programmed death-ligand 1 (PD-L1) and blocks the interaction between PD-L1 and the programmed cell death-1 (PD-1) and B7.1 receptors. This activity removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell function.
Pharmacokinetics:
Distribution: Crosses placenta.
Metabolism: Metabolised via catabolic pathways.
Excretion: Elimination half-life: 6.1 days.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light. Diluted solution: Store between 20-25°C for up to 4 hours or between 2-8°C for up to 24 hours.
Phân loại MIMS
Phân loại ATC
L01XC31 - avelumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
References
Anon. Avelumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 05/03/2020.

Anon. Avelumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/08/2019.

Bavencio 20 mg/mL Concentrate for Solution for Infusion (Merck Europe B.V.). European Medicines Agency [online]. Accessed 05/03/2020.

Bavencio Solution for Injection (EMD Serono, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 30/08/2019.

Buckingham R (ed). Avelumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/08/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Avelumab từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2020 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in